Date: 2014-07-14
Type of information: Product acquisition
Compound: Sollpura® (liprotamase)
Company: Anthera Pharmaceuticals (USA - CA), Eli Lilly (USA - IN)
Therapeutic area: Pancreatic diseases - Metabolic diseases - Rare diseases
Type agreement: product acquisition
Action mechanism: Sollpura® is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis, and potentially other diseases. EPI is characterized by low absorption of fat and other nutrients due to a reduction in digestive enzymes produced by the pancreas. Unlike other enzyme products for EPI, Sollpura\'s chemical characteristics make it ideal for formulation as either a capsule or sachet product for co-administration with a variety of food products.
Disease: Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases
Details: * On July 14, 2014, Anthera Pharmaceuticals announced that it has acquired Sollpura® (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy (\"PERT\") from Eli Lilly and Company. Anthera intends to sublicense all rights, obligations, and intellectual property for the development and commercialization of Sollpura to Alkira Therapeutics, Inc.. In the future, Alkira will secure appropriate funding as a wholly-owned subsidiary of Anthera to advance Sollpura® into a phase 3 pivotal registration trial as agreed with the FDA in 2013. It is intended that Alkira will make all future contingent milestone payments under the license agreement upon product approval and on certain annual sales achievements and will make royalty payments on any product sales after achieving certain sales thresholds of cumulative net sales of Sollpura®.
Concurrent with the transaction, Anthera announced the appointment of Chuck Olson, D.Sc. as President of Alkira. Dr. Olson will oversee development activities for Sollpura® including product manufacturing for the upcoming phase 3 clinical trial to begin in mid 2015.
Financial terms:
Latest news:
